Trichomegaly of the Eyelashes After Treatment with Erlotinib in Non-small Cell Lung Cancer

Carser, Judith; Summers, Yvonne

doi:10.1016/s1556-0864(15)31640-3

Cited by 17 publications

(20 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The skin rash is associated with favorable response to the treatment2. EGFR TKIs-associated trichomegaly of eyelash has been sporadically reported and its incidence is unknown3-7. As lung cancer physicians utilize EGFR TKIs with increasing frequency, they are needed to pay attention to various untoward effects of the drugs.…”

Section: Introductionmentioning

confidence: 99%

Erlotinib Induced Trichomegaly of the Eyelashes

et al. 2013

View full text Add to dashboard Cite

Epithelial growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have been widely used for non-small-cell lung cancer patients. Its untoward cutaneous effects are largely well known and developed in many patients treated with EGFR TKIs. However trichomegaly of eyelash is rarely reported. Although trichomegaly is not a drug-limiting side effect, it could be troublesome of continuing the treatment because of cosmetic issue or eyeball irritation by long eyelashes. Therefore clinicians are needed to pay attention to this uncommon effect. We herein describe erlotinib induced trichomegaly of eyelashes in a woman with adenocarcinoma of the lung.

show abstract

Section: Introductionmentioning

confidence: 99%

Erlotinib Induced Trichomegaly of the Eyelashes

et al. 2013

View full text Add to dashboard Cite

show abstract

“…It was also described in acquired hypertrichosis in patients infected with HIV type 1 (21) or secondary to certain drugs such as zidovudine (22). In patients with lung cancer, trichomegaly uncommonly occurs after treatment with EGFR-TKIs, such as erlotinib (23–26) and gefitinib (14,27) or the EGFR monoclonal antibody, cetuximab (28). In the present cases, their eyelashes became curly, brittle, irregular and elongated after administration of erlotinib.…”

Section: Discussionmentioning

confidence: 99%

Trichomegaly and scalp hair changes following treatment with erlotinib in pulmonary adenocarcinoma patients: A case report and literature review

Zheng

Zhang

et al. 2016

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

Erlotinib is among the oral EGFR-tyrosine kinase inhibitors used to treat non-small cell lung cancer. The common side effects of erlotinib include acne form rash and diarrhea. Eyelash trichomegaly and alterations of scalp hair are rarely observed symptoms. In the present study, we report changes in eyelash trichomegaly and scalp hair in six cases of pulmonary adenocarcinoma patients that had been administered erlotinib. The symptoms of eyelash trichomegaly include curly, irregular, excessively long and brittle eyelashes, and alterations of scalp hair include curly or straight, brittle, fine or rigid, reduced growth rate and volume. Since these side effects does not substantially impact patient quality of life, no treatments were administered. These changes in eyelashes and scalp hair gradually disappeared after withdrawal of erlotinib.

show abstract

“…Non-ophthalmologists should be aware of the side effects of topical prostaglandin analoguesnow commonly prescribed as first-line treatment for glaucoma-which can increase the iris pigmentation and cause the eyelashes to grow longer, darker, and thicker. To the best of our knowledge, this is the third case report in the literature of trichomegaly induced by erlotinib (Carser & Summers, 2006;Lane & Goldstein, 2007). Ocular side effects, although not sightthreatening and generally mild, are encountered with EGFR inhibitors, and it is important to identify and treat them, enhancing patient's compliance and quality of life.…”

mentioning

confidence: 87%